Cargando…

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF

OBJECTIVE: The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Möhn, Nora, Pfeuffer, Steffen, Ruck, Tobias, Gross, Catharina C., Skripuletz, Thomas, Klotz, Luisa, Wiendl, Heinz, Stangel, Martin, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007635/ https://www.ncbi.nlm.nih.gov/pubmed/31826986 http://dx.doi.org/10.1212/NXI.0000000000000654

Ejemplares similares

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2020)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
por: Loos, Julia, et al.
Publicado: (2020)

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function
por: Kleffner, Ilka, et al.
Publicado: (2017)

Classification of neurological diseases using multi-dimensional CSF analysis
por: Gross, Catharina C, et al.
Publicado: (2021)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
por: Schröder, Jens B., et al.
Publicado: (2018)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency
por: Pfeuffer, Steffen, et al.
Publicado: (2020)

Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking
por: Posevitz-Fejfár, Anita, et al.
Publicado: (2014)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis()
por: Deppe, Michael, et al.
Publicado: (2013)

Cytotoxic CD8(+) T cells and CD138(+) plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies
por: Melzer, Nico, et al.
Publicado: (2012)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
por: Krämer, Julia, et al.
Publicado: (2020)

Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis
por: Thomas, Christian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_62rpq4c3h6s2hen6cct4j7ie2h